Metronomic oral vinorelbine for the treatment of advanced non-small cell lung cancer: a multicenter international retrospective analysis

  • A. Camerini
  • G. L. Banna
  • S. Cinieri
  • A. Pezzuto
  • M. Mencoboni
  • F. Rosetti
  • A. Figueiredo
  • P. Rizzo
  • A. Ricci
  • L. Langenhoven
  • A. Santo
  • A. Addeo
  • D. Amoroso
  • F. Barata
Research Article



Metronomic oral vinorelbine (MOV) could be a treatment option for unfit patients with advanced non-small cell lung cancer (NSCLC) based on its safety profile and high patient compliance.


We retrospectively collected data on 270 patients [median age 76 (range 48–92) years, M/F 204/66, PS 0 (27)/1 (110)/≥ 2 (133), median of 3 serious comorbidities] with stage IIIB-IV NSCLC treated with MOV as first (T1) (67%), second (T2) (19%) or subsequent (T3) (14%) line. Schedules consisted of vinorelbine 50 mg (138), 40 mg (68) or 30 mg (64) three times a week continuously.


Patients received an overall median of 6 (range 1–25) cycles with a total of 1253 cycles delivered. The overall response rate was 17.8% with 46 partial and 2 complete responses and 119 patients (44.1%) experienced stable disease > 12 weeks with an overall disease control rate of 61.9%. Median overall time to progression was 5 (range 1–21) months [T1 7 (1–21), T2 5.5 (1–19) and T3 4 (1–19) months] and median overall survival 9 (range 1–36) months [T1 10 (1–31), T2 8 (1–36) and T3 6.5 (2–29) months]. Treatment was extremely well tolerated with 2% (25/1253) G3/4 toxicity (mainly G3 fatigue and anemia) and no toxic deaths. We observed the longer OS 14 (range 7–36) months in a subset of squamous NSCLC patients receiving immunotherapy after metronomic oral vinorelbine.


We confirmed MOV as an extremely safe treatment in a large real world population of advanced NSCLC with an interesting activity mainly consisting of long-term disease stabilization. We speculate the possibility of a synergistic effect with subsequent immunotherapy.


Non-small cell lung cancer Metronomic Oral vinorelbine Elderly Unfit patients 



This study was funded by an unrestricted grant from Lega Italiana per la Lotta contro i Tumori (L.I.L.T.) Sezione Provinciale Lucchese to AC. The authors are grateful to Miss Lara Camerini for editorial assistance and language revision.


This study was funded by an unrestricted grant from Lega Italiana per la Lotta contro i Tumori (L.I.L.T.) Sezione Provinciale Lucchese to AC.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    André N, Carré M, Pasquier E. Metronomics: towards personalized chemotherapy? Nat Rev Clin Oncol. 2014;11:413–31.CrossRefGoogle Scholar
  2. 2.
    Banna GL, Camerini A, Bronte G, et al. Oral metronomic vinorelbine in advanced non-small cell lung cancer patients unfit for chemotherapy. Anticancer Res. 2018;38:3689–97.CrossRefGoogle Scholar
  3. 3.
    Bilir C, Durak S, Kizilkaya B, et al. Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status. Curr Oncol. 2017;24:e199–204.CrossRefGoogle Scholar
  4. 4.
    Bocci G, Kerbel RS. Pharamacokinetics of metronomic chemotherapy: a neglected but crucial aspect. Nat Rev Clin Oncol. 2016;13:569–673.CrossRefGoogle Scholar
  5. 5.
    Briasoulis E, Aravantinos G, Kouvatseas G, et al. Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. BMC Cancer. 2013;13:263.CrossRefGoogle Scholar
  6. 6.
    Camerini A, Puccetti C, Donati S, et al. Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial). BMC Cancer. 2015;15:359.CrossRefGoogle Scholar
  7. 7.
    Camerini A, Valsuani C, Mazzoni F, et al. Phase II trial of single agent oral vinorelbine in elderly (≥ 70 years) patients with advanced non-small cell lung cancer and poor performance status. Ann Oncol. 2010;21:1290–5.CrossRefGoogle Scholar
  8. 8.
    Cazzaniga ME, Camerini A, Addeo R, et al. Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development. Future Oncol. 2016;12:373–87.CrossRefGoogle Scholar
  9. 9.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefGoogle Scholar
  10. 10.
    Ferlay J, Soerjomataram I, Ervik M, et al. [homepage on the Internet]. GLOBOCAN 2012-lung cancer incidence and mortality worldwide. Accessed 15 Sept 2015.
  11. 11.
    Gironès Sarriò R, Antonio Rebollo M, Molina Garrido MJ, et al. On the behalf of the Spanish Working Group on Geriatric Oncology of the Spanish Society of Medical Oncology (SEOM). General recommendations paper on the management of older patients with cancer: the SEOM geriatric oncology task force’s position statement. Clin Transl Oncol. 2018. Scholar
  12. 12.
    Gridelli C, Morabito A, Cavanna L, et al. Cisplatin-based first-line treatment of elderly patients with advanced non-small-cell lung cancer: joint analysis of MILES-3 and MILES-4 phase III trials. J Clin Oncol. 2018;36:2585–92.CrossRefGoogle Scholar
  13. 13.
    Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advance non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–72.CrossRefGoogle Scholar
  14. 14.
    Griffin AM, Butow PN, Coates AS, et al. On the receiving end V: patient perceptions of the side effects of cancer chemotherapy in. Ann Oncol. 1993;7:189–95.CrossRefGoogle Scholar
  15. 15.
    Lilenbaum R, Villaflor VM, Langer C, et al. Single-agent versus combination chemotherapy in patients with advanced non-small cell lung cancer and a performance status of 2: prognostic factors and treatment selection based on two large randomized clinical trials. J Thor Oncol. 2009;4:869–74.CrossRefGoogle Scholar
  16. 16.
    Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.CrossRefGoogle Scholar
  17. 17.
    Mencoboni M, Filiberti RA, Taveggia P, et al. Safety of first-line chemotherapy with metronomic single-agent oral vinorelbine in elderly patients with NSCLC. Anticancer Res. 2017;37:3189–94.PubMedGoogle Scholar
  18. 18.
    Molina JR, Yang P, Cassivi SD, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584–94.CrossRefGoogle Scholar
  19. 19.
    Planchard D, Popat S, Kerr K, et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol Suppl. 2018;4:iv192–iv237.CrossRefGoogle Scholar
  20. 20.
    Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011;378:1079–88.CrossRefGoogle Scholar
  21. 21.
    Repetto L, Balducci L. A case for geriatric oncology. Lancet Oncol. 2002;3:289–97.CrossRefGoogle Scholar
  22. 22.
    Stewart BW, Wild CP. World cancer report 2014. Lyon: International Agency for Research on Cancer (IARC)-World Health Organization; 2014.Google Scholar
  23. 23.
    The Elderly Lung Cancer Vinorelbine Italian Study group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer. J Natl Cancer Inst. 1999;85:365–76.Google Scholar
  24. 24.
    U.S. Department of Health and Human Services (2010). Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health National Cancer Institute. May 28 2009 (v4.03: June 14, 2010).Google Scholar
  25. 25.
    Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the use of surveillance data for cancer prevention and control. J Natl Cancer Inst. 2003;95:1276–99.CrossRefGoogle Scholar

Copyright information

© Federación de Sociedades Españolas de Oncología (FESEO) 2018

Authors and Affiliations

  • A. Camerini
    • 1
  • G. L. Banna
    • 2
  • S. Cinieri
    • 3
  • A. Pezzuto
    • 4
  • M. Mencoboni
    • 5
  • F. Rosetti
    • 6
  • A. Figueiredo
    • 7
  • P. Rizzo
    • 3
  • A. Ricci
    • 8
  • L. Langenhoven
    • 9
  • A. Santo
    • 10
  • A. Addeo
    • 11
  • D. Amoroso
    • 1
  • F. Barata
    • 7
  1. 1.Medical OncologyVersilia Hospital – ASL Toscana Nord-OvestLido di CamaioreItaly
  2. 2.Division of Medical OncologyCannizzaro HospitalCataniaItaly
  3. 3.Medical OncologyPerrino HospitalBrindisiItaly
  4. 4.Department of Cardio-Thoracic-Vascular ScienceS. Andrea HospitalRomeItaly
  5. 5.Medical OncologyASL 3 Genovese, Ospedale Villa ScassiGenoaItaly
  6. 6.Medical OncologyULSS3 Serenissima, Distretto Mirano-DoloDoloItaly
  7. 7.PneumologyCentro Hospitalar e Universitario de CoimbraCelas-CoimbraPortugal
  8. 8.Department of Molecular and Clinical MedicineS. Andrea HospitalRomeItaly
  9. 9.Clinical OncologyPanorama Oncology CentreCape TownSouth Africa
  10. 10.Medical OncologyUniversity Hospital of VeronaVeronaItaly
  11. 11.Oncology DepartmentUniversity Hospital GenevaGenevaSwitzerland

Personalised recommendations